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Abstract
Destruction of cancer cells by genetically modified viral and nonviral vectors has been the aim of many research
programs. The ability to target cytotoxic gene therapies to the cells of interest is an essential prerequisite, and the
treatment has always had the potential to provide better and more long-lasting therapy than existing che-
motherapies. However, the potency of these infectious agents requires effective testing systems, in which hy-
potheses can be explored both in vitro and in vivo before the establishment of clinical trials in humans. The real
prospect of off-target effects should be eliminated in the preclinical stage, if current prejudices against such
therapies are to be overcome. In this review we have set out, using adenoviral vectors as a commonly used
example, to discuss some of the key parameters required to develop more effective testing, and to critically
assess the current cellular models for the development and testing of prostate cancer biotherapy. Only by
developing models that more closely mirror human tissues will we be able to translate literature publications
into clinical trials and hence into acceptable alternative treatments for the most commonly diagnosed cancer in
humans.
Introduction
The limited long-term in vivo efficacy of biologicaltherapies for human prostate cancer (Maitland et al.,
2004) can be ascribed to a number of different causes: First, the
entire concept could be wrong, that is, the gene or pathway to
be exploited, perhaps discovered in cell line experiments, is
simply not differentially expressed to the same extent in vivo;
second, the agent itself could be wrong or inactive, perhaps
unable to survive in the in vivo environment, or unable to
penetrate cells while retaining its activity against the primary
target; last, and often neglected, is that although the concept
might be strong, and the agent active, the testing system used
to define efficacy (and safety) could be defective.
Validity of Cell Lines That Represent Prostatic Disease
Prostate cancer has been poorly served by the establish-
ment of cell lines. In general, new agents for prostate cancer
are tested mainly in three cell types; PC3, LNCaP, and
DU145. A review of the gene therapy literature suggests
there are 2650 PubMed references that include the terms
prostate cancer and gene therapy. Of those, 562 employ only
LNCaP cells; PC3 cells are used in 153 and DU145 cells in
179. The remainder employ a mixture of all three. In reality,
only relatively few published studies make it through to the
clinic. The Journal of Gene Medicine database (March 2009;
http:==www.wiley.co.uk=genmed=clinical=) lists the actual
number of prostate cancer clinical trials as considerably
lower (105): a conversion rate of 4%. In fact, many of the
reported trials are derivative, so the actual rate is closer to
1%. Later stage clinical trials have been dominated by vac-
cine approaches to augment antitumor responses without
any need to target the tumor itself (Small et al., 2004).
The LNCaP, PC3, and DU145 cell lines were derived al-
most 30 years ago from therapy-resistant metastatic cancers
(Table 1). The TSU-Pr1 cell line was also considered to be
from prostate, but was subsequently shown to be derived
from the human bladder cancer cell line T24 (van Bokhoven
et al., 2001). What is frequently lacking from these models is
any representation of untreated low Gleason grade tumors
within the prostate (Gleason, 1966), which have a high de-
gree of normal prostate differentiation, or less structured,
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Table 1. Cell Lines from Human Prostate for Vector Testing
Cell line
Androgen
sensitivity Derivation Ref.
Normal/
nonmalignant
PNT2 No Derived from normal prostate epithelium by
transfection of an ori mutant of SV40
Cussenot et al. (1991)
PNT1 No Derived from normal prostate epithelium by
transfection of an ori SV40 plasmid
Cussenot et al. (1991)
BPH1 Noa Benign prostatic tissue after SV40 large-T
antigen immortalization of primary cells
Hayward et al. (1995)
PZ-HPV-7 No Derived from epithelial cells cultured from
normal tissue from the peripheral zone
of the prostate by transfection with HPV18 DNA
Weijerman et al. (1994)
RWPE-1 Noa Peripheral zone of a histologically normal
adult human prostate transfected with a
single copy of HPV18
Bello et al. (1997)
PWR-1E Noa Human prostatic epithelial cells, derived
from a normal prostate with mild hyperplasia,
were immortalized with an adenovirus 12--SV40
hybrid virus (Ad12-SV40)
Webber et al. (1996)
WPMY-1 ND A myofibroblast stromal cell line derived from
stromal cells from the peripheral zone of the
histologically normal adult prostate, immortalized
with SV40 large-T antigen gene
Webber et al. (1999)
RC156N=hTERT No hTERT-immortalized nonmalignant human
prostate epithelial cell
Miki et al. (2007)
Premalignant
P4E6 No Derived from Gleason 2þ 2 (low-grade cancer)
by retrovirus-mediated introduction of an HPV16
E6 gene
Maitland et al. (2001)
RWPE-2 Noa Derived from RWPE-1 cells by transformation with
Ki-ras, using the Kirsten murine sarcoma virus
(Ki-MuSV): RWPE2-W99 was further selected by
cloning in soft agar to select cells that show
high expression of Ki-ras
Bello et al. (1997)
WPE1-NA22
WPE1-NB14
WPE1-NB11
WPE1-NB26
Noa WPE1-Nxx cells were derived from RWPE-1 cells after
exposure to N-methyl-N-nitrosourea
Webber et al. (2001)
WPE1-NB26-64
WPE1-NB26-65
ND WPE1-NB26-64 and WPE1-NB26-65 (CRL-2890;
ATCC) were derived from a subcutaneous tumor
in a nude mouse injected with WPE1-NB26
Rivette et al. (2005)
WPE-stem
WPE-int
ND WPE-stem and WPE-int cells were derived from
the RWPE-1 cell line after two consecutive
cycles of single-cell cloning
Tokar et al. (2005)
Carcinoma
MDA PCa 2b Yes MDA PCa 2b was established from a bone metastasis
of androgen-independent adenocarcinoma
of the prostate
Navone et al. (1997)
NCI-H660 ND Has the appearance and many (but not all) of the
properties of small-cell carcinoma of the prostate
Gazdar and Minna (1996)
LAPC-4 Yes Grown from androgen-sensitive lymph node
metastasis of prostate cancer
Klein et al. (1997)
CA-HPV-10 Yes CA-HPV-10 was derived from cells from a prostatic
adenocarcinoma of Gleason grade 4=4. The
cells were transformed by transfection with
HPV18 DNA
Weijerman et al. (1994)
DU145 No Cultured from a brain metastasis of prostate cancer Stone et al. (1978)
22Rv1 Yes 22Rv1 is a human prostate carcinoma epithelial cell
line derived from a xenograft of a primary prostate
cancer that was serially propagated in mice
after castration-induced regression and relapse of
the parental, androgen-dependent CWR22 xenograft
Sramkoski et al. (1999)
(continued)
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untreated but ‘‘undifferentiated’’ higher Gleason grade tu-
mors. As screening and diagnostic techniques improve for
prostate cancer (Schro¨der et al., 2009), ‘‘clinical’’ prostate
cancers will be downgraded to lower Gleason grades, which
will comprise the primary target for new therapies. At
present, however, most biotherapies are used as a ‘‘last re-
sort’’ after failure of hormone therapy, radiotherapy, and
chemotherapy.
It is common in studies of new agents for prostate cancer
to demonstrate their efficacy on one or more cancer cell lines,
but only rarely do the experiments offer any estimation of
damage to the normal prostate, as the prostate is considered
a nonessential organ. Nonmalignant cell lines (Maitland et al.,
2001; Peehl, 2005) are listed in Table 1 along with many of
the existing cancer cell lines. Primary cell cultures (see later),
grown in a serum-free or low-serum medium, are frequently
used as a comparator with the established cancer cell lines.
These primary cultures are of a basal cell type, unless in-
duced to differentiate by growth in a medium supplemented
with serum, calcium, and androgens (Collins et al., 2005).
Similarly, most nonmalignant epithelial cell lines from pros-
tate are also basal in phenotype, and express cytokeratin-
5=14, but not the androgen receptor.
Thus, when studying vector-mediated gene transfer effi-
ciencies in prostate cell cultures, one must be careful which
parameter is under study, for example, between androgen-
sensitive and androgen-insensitive cancers. In this case the
comparison is frequently between LNCaP and PC3=DU145.
This is more precisely a comparison of luminal cells and
basal cells, and a better comparison would be LNCaP with
one of the many derived androgen receptor-negative sub-
clones such as C4-2 (Wu et al., 1994). The comparison of the
more recently established wild-type androgen receptor-
expressing PC346C with one of its androgen receptor-
negative subclones provides an even more clinically relevant
alternative (Marques et al., 2005, 2006).
It was the aim of the GIANT (Gene Therapy: An In-
tegrated Approach to Neoplastic Treatment) program
(www.giant.eu.com) to assess the validity of the preclinical
testing procedures for near-to-patient testing. As mentioned
previously, cell culture models of prostate epithelium often
lack the luminal differentiation present in tumors, unless
derived from a later stage metastatic tumor. As illustrated in
Fig. 1A, a normal human prostate acinus consists of an upper
luminal layer (60% of epithelial cells), in close contact with a
basal cell layer (40% of epithelial cells). These proportions are
grossly disrupted in higher Gleason grade prostate cancers.
Most untreated hormone-naive prostate cancers have a lu-
minal phenotype (express androgen receptor and luminal
cytokeratin-18) and lack or contain <1% basal cells (no
p63=cytokeratin-5=14 expression). The LNCaP cell line
(Horoszewicz et al., 1980) is frequently used to study hor-
mone-sensitive (luminal) cancer, but LNCaP was isolated
from a patient who had failed a primitive form of anti-
hormone therapy (estramustine chemotherapy) and the cells
express a mutant androgen receptor, which responds equally
well to other steroid hormones (Veldscholte et al., 1990).
Toward Better Preclinical Systems: Vector Adhesion
in Two-Dimensional Cell Cultures
Initial testing of infectious agents in cell cultures is often
optimized for viral replication or infectivity, for example,
attachment of viruses to the cell surface. Many viruses use
adhesion molecules as receptors and adenovirus is no
exception (reviewed in Greber and Gastaldelli, 2007). For
example, the main adenovirus receptor, the coxsackievirus–
adenovirus receptor (CAR), forms homodimers between
contacting cells and serves as a cell adhesion molecule (van
Raaij et al., 2000), but adenoviruses also require a secondary
receptor in the form of integrins for high-efficiency trans-
duction. Of these, avb3 is probably the key integrin involved
in virus uptake (Wickham et al., 1993; Nemerow, 2000). CAR
protein is also expressed in mobile membrane lipid rafts
(Ashbourne Excoffon et al., 2003) and coimmunoprecipitates
with ZO-1, a tight junction protein (Cohen et al., 2001).
Table 1. Continued
Cell line
Androgen
sensitivity Derivation Ref.
RC-92a=hTERT No hTERT-immortalized intraprostatic tumor
epithelial cell
Miki et al. (2007)
DuCaP Yes Established from a metastatic lesion to the dura
mater of a patient with hormone-refractory prostate
cancer
Lee et al. (2001)
VCaP Yes This line was established in 1997 from a vertebral bone
metastasis from a patient with hormone-refractory
prostate cancer. It was passaged as xenografts
in mice and then cultured in vitro
Korenchuk et al. (2001)
LNCaP Yes Derived from a lymph node metastasis of prostate
cancer after estramustine treatment
Horoszewicz et al. (1980)
C4-2 No Androgen-independent subclone of LNCaP parent Wu et al. (1994)
PC-3 No Derived from an androgen-independent bone
metastasis of a treatment-resistant prostate cancer
Kaighn et al. (1979)
PC3M The M variant was selected for enhanced
metastatic spread
Abbreviations: ATCC, American Type Culture Collection; HPV, human papilloma virus; hTERT, human telomerase reverse transcriptase;
ND, not determined; SV40, simian virus 40.
aCan be induced to express androgen receptor and luminal markers by culture in three dimensions and=or androgens.
EFFECTIVE TESTING OF PROSTATE CANCER BIOTHERAPY 817
In normal prostate tissues, CAR is located at the lateral
junctions between luminal cells, and at the apical border,
whereas in basal cells mostly cytoplasmic expression is ob-
served (Rauen et al., 2002). Prostate cancer is mainly luminal
in phenotype, which suggests it should express more CAR,
as application of hormones to rat seminal vesicle and prostate
epithelium results in a reorganization and differentiation-
regulated increase in junction formation (Ortiz and Ca-
vicchia, 1990; Mitra et al., 2006). However, in sections of
prostate cancer, the expression of CAR is lost at the cell
junctions and also decreases at the protein level (Li et al.,
1999; Okegawa, 2000). Therefore the viral vectors may find
alterative means of entry, for example, adenovirus may enter
through direct contact of the penton base with integrins or
other receptors. The loss of CAR was confirmed in our lab-
oratory, where we could not detect expression at the apical
border of primary prostate cancer samples (K. Chambers,
unpublished data). Although the common productive cell
line for adenoviral culture, HEK-293, has extensive intracel-
lular CAR (Fig. 1B), in prostate cancer cell lines, such as
FIG. 1. A model for virus binding and penetration in prostate epithelium. (A) Differences between (left) an organized
bilayered normal prostate epithelium and (right) the mainly luminal, less organized cancer epithelium (in a higher grade
tumor). The principal adenovirus attachment protein, CAR (red dots), may be associated with the apical or basal side of the
tight junction. If associated with the apical side then it is available for primary binding to the fiber knob of adenovirus. If
below the tight junction then it is not available for binding. It is known that disruption of the tight junctions increases
infection with adenovirus, probably because of increased accessibility of CAR on the basal side of the tight junction. In
prostate cancers the structural disruption due to aberrant differentiation could prevent viral spread and penetration, in a
therapeutic setting. (B and C) Immunocytochemical detection of coxsackievirus–adenovirus receptor protein in cultured
prostate cancer cells. CAR (green) is expressed at lateral cell junctions in (B) HEK-293 cells and (C) LNCaP cells and
colocalizes (yellow) with F-actin (red). DAPI (blue) was used to visualize nuclei. Note the various CAR densities, the
localization of CAR at intracellular junctions, and the striking changes in CAR expression, according to cell density, in the
two cell cultures. Scale bars: 50 mm.
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LNCaP, CAR is present at lateral junctions but is expressed
mainly in the cytoplasm of single cells without adhesions
(Fig. 1C; and K. Chambers, unpublished data). CAR is,
however, still detectable in subconfluent prostate cancer cell
cultures even after disruption of the junctions for flow cy-
tometric analysis (Pandha et al., 2003).
Because of the expression of CAR at the tight junctions, the
availability of the receptor from the luminal surface is blocked
by their proximity to or incorporation into tight intracellular
junctions (Balda and Matter, 1998; Cohen et al., 2001). Access
and spread can be governed by restricted access to receptor
complexes, as the mean distance between cells in tight and
gap junctions is 1.5 and 4nm, respectively, whereas the full
diameter of many nonviral particles is at least 50 nm and that
of the rigid adenoviral particle is 100nm.
With prostate cancers, there is also the question of the cell
surface available to be infected in a structured and polarized
epithelium (present in most lower Gleason grade tumors).
In vivo, it is likely that infection will occur through the lu-
minal surface (see Fig. 1A) rather than through basal contact
via the basement membrane, which adenoviruses can fail to
penetrate, although genetic modification of the virus by re-
placement of the E3 gene to encode the relaxin-degradative
enzyme can improve penetration (Kim et al., 2006). Other
strategies to improve infectivity via CAR include internali-
zation of tight junction proteins such as occludin to expose
the tight junction receptor CAR, without affecting the dis-
tribution of other tight junctional proteins (Coyne et al.,
2007), and increased exposure of CAR through actin re-
modeling (Coyne and Bergelson, 2005).
In tissues, the damage induced by direct injection results
in effective infection restricted to a few millimeters around
needle tracks (Patel et al., 2009). Therefore it will probably
never be possible in vivo to saturate a tumor with prodrug-
activating cells after gene transduction by intratumoral in-
jection of even high titers of the most efficient vectors,
without facilitating intratumoral spread. It was for this rea-
son that an oncolytic approach was taken for the initial trials
in GIANT (Cheng et al., 2006), where intracellular spread
occurs after infected cell lysis.
However, in immunocompetent patients such spread is a
matter of timing between the triggering of a potent immune
response against adenoviruses and the ability of the virus to
reinfect multiple times. Although the immune response may
be restrictive in the spread of the virus (Parato et al., 2005),
there is evidence to suggest that patients who respond im-
munologically to a therapeutic viral infection also mount a
powerful immune response against tumor cell antigens. The
strong adjuvant effect of high levels of viral antigens is
thought to be responsible, resulting in regression of not only
the primary tumor, but also of distant metastases (Freytag
et al., 2002). This type of outcome emphasizes the need to use
virotherapies in immunocompetent patients to achieve max-
imal therapeutic efficacy. Predictably, in most phase 1 (in
which safety assessment is the object) but more surprisingly
in phase 2 (in which efficacy is sought) clinical trials of bio-
therapies, this is seldom the case.
Primary Tissue Infections
An excellent model, which takes into account differential
patient susceptibility to infection, is direct infection of needle
biopsies from fresh prostate cancer tissues, in which tissue
architecture and viability can be preserved in culture for a
period of up to 2 weeks in a basal medium. Such tests pro-
vide, on a patient-to-patient basis, a measurement of sus-
ceptibility not only to gene therapy agents but also to many
common chemotherapies. However, ethical restrictions in
obtaining fresh tissues, or the risk of compromising patho-
logical diagnosis, can compromise the quantities of tissue
available to do such studies in a rational and quantitative
way.
A good alternative would be to establish and test the
transduction of fragments of tissue as primary xenografts in
immunocompromised mice. Short-term ‘‘culture’’ of human
tissues is possible in xenografts, with maintenance of both
tissue architecture and hormone responsiveness at subcuta-
neous, subrenal capsule, and orthotopic mouse prostate sites.
Although the production of such xenografts can be labor
intensive, and they are limited in size and scope for the
testing of agents, they do offer the best measurement of
therapeutic effectiveness as a patient-specific medicine, the
‘‘gold standard’’ for sophisticated and targeted biotherapies.
Within the GIANT program we have used xenograft models,
established for many years (Table 2).
Primary Epithelial Cell Cultures
As an interim solution, in vitro cultures of primary pros-
tate cancers can be employed. Primary cells have a limited
life span in culture, especially in medium containing high
fetal calf serum concentrations, which is used to promote
rapid growth of not only the primary epithelial cultures, but
also the fibroblasts. These culture conditions also stimulate
the terminal differentiation of basal epithelial cells. Normal
prostate luminal epithelium has a limited ability to persist
in vitro and in vivo, whereas it is the basal epithelium that is
responsible for driving organ regeneration after castration
(Isaacs and Kyprianou, 1987) and has a much higher fre-
quency of mitosis compared with the luminal epithelium.
Apoptotic rates are higher (De Marzo et al., 1998) and mi-
toses are barely detectable in normal luminal cells (Fig. 1),
which can be considered the end-stage of a differentiation
process, in which cells are shed into the lumen and often
appear in the bloodstream as apoptotic or preapoptotic
bodies. This is also true in tumors, where circulating tumor
cells are mostly of a differentiated phenotype (PSAþ,
CK18þ), many of which are not viable (Riethdorf and Pantel,
2008). It is perhaps due to the high apoptotic rate in the
luminal fraction that successful primary cultures of normal
human prostate are of a basal cell type. We have not yet
solved the problem of both differentiation and apoptosis
within these cultures, which is frequently linked to the
presence of high amounts of prostate stroma copurified from
the dissociated tissues (Cunha, 1984; Hall et al., 2002). To
eliminate or reduce the stromal content, cholera toxin can be
used along with other epithelial growth-promoting factors
within the cell culture medium (Chung et al., 1988; Marques
et al., 2005). Tissue dissociation and cell fractionation, for
example, by means of immunomagnetic beads, effectively
removes all prostate stroma and additional purification by
promoting adherence to basement membrane or collagen
provides further reduction of both luminal and stromal cells
(Richardson et al., 2004).
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To at least partly restore luminal differentiation, recon-
structions of the multilayered and multicellular prostatic
epithelium can be achieved in two dimensions by allowing
the epithelial cells to grow out of monolayer and form a
bilayer. Induction of luminal differentiation is further en-
hanced by addition of prostate androgen-responsive stroma
and medium supplements such as dihydrotestosterone and
calcium, resulting in a polarization of the epithelial layers. At
this point the characteristic patterns of expression of cell
surface receptors are found, as gene expression switches
from basal to luminal cytokeratin expression in the upper
(luminal) layer (Swift et al., 2010).
Three Dimensions: Better Than Two?
Whereas two-dimensional cell culture presents a single
surface for virus infection, tissues exist in vivo as multiple
layers bordered by tight junctions and desmosomes, and
containing a multitude of different structurally differentiated
cell types, which will inhibit vector penetration. One way
to model this is to generate three-dimensional structures in
cell culture. To assess the effects of differentiation, three-
dimensional cultures can be induced to both polarize and
differentiate by suspension in an appropriate matrix, the
stimulus to polarize being provided by signals from prostate
stromal cells (Lang et al., 2001).
Adenoviruses have a limited ability to extravasate from
blood vessels, unless the capillaries are severely damaged or
are irregular in development, such as is the case with in-
tratumoral capillaries (Wang and Yuan, 2006). When ade-
novirus was administered via the intravenous route in mice
xenografted with a human prostate tumor, infection was
observed mainly in endothelial cells of healthy vessels in the
tumor. Few infected tumor cells were detectable after intra-
venous administration. However, when virus was adminis-
tered intratumorally in the same model, many infected
tumor cells were detected, although the distribution pattern
remained concentrated around the needle track (R. Kraaij,
unpublished). Complex three-dimensional structures in vitro
can also address the issue of penetration.
In another tissue, that is, infections of the eye, adeno-
viruses were also unable to penetrate the outer layers of
epithelium to infect the basal epithelium, whereas enveloped
viruses of less rigid structure, such as baculovirus (mean
diameter, 60 nm), could do so (Kinnunen et al., 2009). This
suggests that particle diameter is not the only parameter to
take into account in determining tissue penetration.
To model tissue penetration in the GIANT program, three-
dimensional spheroids grown from a number of different
prostate cell lines were employed. Different morphologies of
spheroid were derived from the different cell types (Fig. 2).
Some were rigid and heavily structured, whereas others
were much more loosely associated, in which the require-
ment to form structures and to communicate with other cells
had been gradually lost either as a result of oncogenic
changes, or through long-term culture. In such full three-
dimensional models (Lang et al., 2001) it became apparent
that most vectors, including adenoviruses, had difficulties in
penetrating basement membranes such as Matrigel, which
reflects restrictions on their spread in tissues in vivo as well.
However, even more striking was the inability of adeno-
viruses to pass through and penetrate organized spheroids
as shown in Fig. 2A and B. Furthermore, P4E6 cells (derived from
a well-differentiated prostate cancer) form a highly organized
spheroid (Fig. 2C), which also contains a stretched layer of
thin epithelium to provide structural integrity. Both by
immunofluorescence (Fig. 2A and B) and by electron mi-
croscopy (Fig. 2D), virus replication could be seen within the
outer layer of spheroid epithelium, but spread within the
spheroid was almost totally absent. When yields of oncolytic
virus in this system were compared with the yields from a
replicating monolayer culture and subsequently with xeno-
grafts (see later), the three-dimensional culture more closely
matched the situation in xenograft models (L. Georgopoulos,
H. Evans, and R. Nugent, unpublished data).
Cellular Heterogeneity in Prostate Cancer
For most cancer medicines, there has long been the as-
sumption that all the cells in a tumor grow more quickly than
Table 2. Human Prostate Cancer Xenograft Modelsa
Name
Derived
from:
Androgen
responsive PSA AR
Year
derived
PC-82 Prostate Yes Yes Yes 1977
PC-133 Bone No No No 1981
PC-135 Prostate No No No 1982
PC-EW Prostate Yes Yes Yes 1981
PC-295 LN Yes Yes Yes 1991
PC-310 Prostate Yes Yes Yes 1991
PC-324 TURP No No No 1991
PC-329 Prostate Yes Yes Yes 1991
PC-339 TURP No No No 1991
PC-346 TURP Yes Yes Yes 1991
PC-346I PC-346 No Yes Mutant 1992
PC-346B TURP Yes Yes Yes 1991
PC-346BI PC-346B No Yes Yes 1992
PC-374 Skin Yes Yes Yes 1992
TEN12 Prostate Yes Yes Yes 1985
LuCaP 23.1 Lymph
node
Yes Yes 1996
LuCaP 23.8 Lymph
node
Yes Yes 1996
LuCaP 23.12 Liver Yes Yes 1996
LuCaP 35 Lymph
node
Yes Yes Yes 2003
LuCaP 35V LuCap 35 No 2003
LuCaP 49 Metastasis No No No 2002
LAPC-3 AI TURP No Yes=no Yes 1999
LAPC-4 AI LN Yes Yes Yes 1997
LAPC-9 AI Bone
Met
Yes Yes Yes 2001
CWR22 AD Met Yes Yes Mutant 1993
CWR21 AD Met Yes Yes Yes 1993
CWR31 AD Met Yes Yes Yes 1993
CWR91 AD Met Yes Yes Yes 1993
MDA Pca-31 Liver N=A 1998
MDA Pca-40 Liver N=A 1998
MDA Pca-43 Adrenal N=A 1998
MDA Pca-44 Skin N=A 1998
Abbreviations: AD, androgen dependent; AI, androgen indepen-
dent; AR, androgen receptor; LN, lymph node metastasis; Met,
metastasis; N=A, not applicable; PC, prostate cancer; PSA, prostate-
specific antigen; TURP, transurethral resection of the prostate.
aReproduced with permission from van Weerden et al. (2009).
820 MAITLAND ET AL.
their normal counterparts, and that they homogeneously
express the tissue-specific mRNA patterns of a prostate
tumor. The rapid emergence of therapy-resistant tumors,
even for biotherapies, has been cited as proof of the existence
of a preexisting therapy-resistant fraction, sometimes termed
cancer stem cells or tumor-initiating cells (Diehn et al., 2009). In
human prostate cancer, this fraction seems not to respond to
androgens, which form the basis of much of the tissue-
specific targeting strategies employed in virus targeting
(Maitland and Collins, 2008). As suggested in a review
(Short and Curiel, 2009), the development of new genera-
tions of vectors with the ability to eliminate cancer stem cells,
as part of a combined gene therapy approach to shrink tu-
mor bulk, should extend the effectiveness of such therapies.
Contamination of Cell Models
High-throughput testing of infectious agents, relying on
both primary cells and cell lines, also presents a number of
dangers with respect to the validity of the cells to be em-
ployed. It is now mandatory for publication in some journals
that all cell cultures be regularly genotyped. The standard
FIG. 2. Advanced models of prostate cancer. (A) Infection of PC346C and LNCaP spheroids with adenoviruses expressing
GFP from constitutive cytomegalovirus (CMV) and prostate-targeted (PPT) promoters. Note the lack of GFP signal in the
center of the spheroids, indicating lack of viral penetration. (B) Three-dimensional confocal rendering of staining for Ad5
hexon protein (red) in the peripheral layers of a PC346C spheroid infected with prostate-specific PPT oncolytic adenovirus.
Note the restriction of viral replication to the perimeter of the spheroid. (C) Scanning electron micrographs (at increasing
magnification) of three different human prostate cancer cells generating spheroid structures. (D) Top: High-power scanning
electron micrograph of LNCaP spheroid infected with PPT-oncolytic adenovirus (72 hr postinfection). Bottom: A segment of a
transmission electron micrograph of an infected cell from an infected spheroid, showing multiple viral particles and ade-
noviral proteins: lack of viral spread is not due to poor viral replication or assembly. (E) Prostate cancer xenografts in
immunocompetent mice: Histologies of androgen-responsive PC82 tumor (left, hematoxylin staining) and PC310 tumor (right,
androgen receptor staining). (F) Xenograft infection with oncolytic targeted adenovirus: Histology of PC346C tumor 3 days
after infection with the replication-competent Ad-ZH=3 vector (brown, Ad5 hexon staining; purple, hematoxylin staining).
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applied by the American Tissue Culture Collection (ATCC,
Manassas, VA; http:==www.atcc.org=) is the PowerPlex sys-
tem (a microsatellite genotyping kit; Promega, Madison, WI).
All cells to be employed in therapy testing should be geno-
typed initially as primary cells, in comparison with the
original tissue DNA (or lymphocytes). If an established cell
line is used the reference PowerPlex fingerprint is available
from the ATCC. Even primary cultures, from normal or tu-
mor tissues, have a limited life span as a true reflection of the
original tumor, for example, glioblastoma cell cultures (Lee
et al., 2006). This life span can be extended by purifying
different cell populations, including stem cells, as described
previously (Collins et al., 2005).
Second, cells derived from xenografts or primary cultures
passaged on inactivated mouse stromal feeder layers require
routine assessment of human cell content and the presence of
murine cells and DNA, derived either from murine infiltrates
in the xenografts or ‘‘breakthrough’’ of feeder cells resulting
from inadequate inactivation, by polymerase chain reaction
(PCR) using repetitive species-specific centromeric sequences
(Becker et al., 2002).
The last restriction when working with primary tissues,
xenografts (in particular), and established cell lines, is the
necessity to eliminate mycoplasma contamination, which
frequently prevents vector attachment and penetration. A
number of excellent commercial PCR-based assays are
available for mycoplasma detection.
Ex Vivo Clinically Relevant Testing
for Antivector Immunity
One aspect of gene therapy, which cannot be determined
in a standard cell culture environment, concerns exposure of
the infectious agent to the bloodstream and immune system
of the host. The current standard in vivo system, a xenograft
of the original cell line used in cell culture in an immuno-
compromised mouse, suffers 2-fold in this respect.
First, there is no strong humoral or T cell-mediated
immune response against the infectious particles, as the
commonly used nude mouse is athymic. The nonobese dia-
betic-severe combined immunodeficient (NOD-SCID) mouse
lacks more of the T cell immunity in addition to B cells, but is
now being replaced in practical use by even more immu-
nocompromised hosts such as the Rag2=gc double-negative
hosts, which most notably also lack most natural killer (NK)
cell functions (Le De´ve´dec et al., 2009). These hosts still retain
complement responses, but show different abilities to engraft
with human tumor cells. However, all hosts share the in-
ability to mount any immune response to tumor cell lysis
products, acknowledged as one of the major influences on
tumor destruction (see previously).
Second, infectious particles, in particular adenoviruses,
interact in a different way with blood components in murine
and human hosts. It has been shown that more than 90% of
adenovirus administered to human blood ex vivo binds to
human erythrocytes whereas only a negligible fraction
(<0.1%) of adenovirus binds to blood cells in freshly isolated
murine whole blood (Lyons et al., 2006). Human erythrocytes
bind and inactivate adenovirus serotype 5 (Ad5) by expres-
sing both the coxsackievirus–adenovirus receptor (CAR) and
the complement receptor-1 (CR1) (Carlisle et al., 2009).
Mouse erythrocytes do not express either CAR or CR1. Be-
cause complement receptors are important for induction of
neutralizing antibodies (Seregin et al., 2009) mouse blood
does not mimic the situation in human blood, that is, the
effective dose of virus in humans is now calculated to be
much lower than that originally predicted from the critical
preclinical studies in mice.
As part of the GIANT project, we sought to overcome this
by testing vectors in a human ex vivo blood loop system,
which had previously been developed for the testing of other
biomaterials (Hong et al., 2001). This system is a powerful
preclinical model for studies of viral and nonviral vector
interactions with all components of whole blood, omitting
the need for high-level anticoagulants that can alter the re-
sults by chelating the system of positive ions such as Ca2þ
and Zn2þ. Furthermore, in contrast to the use of sealed small-
volume tubes, the loop system also benefits from reproduc-
ing shear forces, which are important for platelet function
and the continuous flow of the bloodstream.
We have previously shown (Georgopoulos et al., 2009) that
a major complement response in blood loops was mounted
against a nonhuman virus, baculovirus. Significant binding
of IgM and complement components was observed and
strong immunoreactivity was characterized by blood clot
formation. The importance of the complement responses to
baculovirus, against which humans should have no immu-
nological memory, was indicated by clot prevention by use
of complement inhibitors such as compstatin (Nilsson et al.,
1998). The life span of the vector particles could therefore be
extended in serum by coinoculation with specific comple-
ment inhibitors.
Within the GIANT network, we have used the blood loop
system to assess the immune response in whole human
blood to an Ad5 vector and immunologically ‘‘stealthed’’
PEGylated Ad5. Such PEGylation of Ad5-based vectors has
proven efficient in reducing the immune response and in-
creasing the circulation times in mouse models (O’Riordan
et al., 1999; Gao et al., 2007) and reducing virus uptake by
mouse Kupffer cells (Mok et al., 2005). PEGylation reduced
Ad5 adhesion to blood cells, and both complement activation
and cytokine release to a certain degree, especially when the
neutralizing anti-Ad5 antibody titer was low (Danielsson
et al., 2010). However, the reductions were lower than would
have been predicted from mouse models (O’Riordan et al.,
1999; Mok et al., 2005; Gao et al., 2007; Wortmann et al., 2008).
The reason may well be the difference in cell adhesion of Ad5
to human and mouse blood cells and the fact that PEGylation
has only a limited protective effect when the neutralizing
anti-Ad5 antibody titers are high. This finding simply em-
phasizes the importance of using a relevant model for eval-
uating viral vectors.
Toward More Clinically Relevant In Vivo Testing
Current modeling of human prostate cancer in animal
models still does not accurately represent the clinical nature
of the human disease. A consensus meeting in the United
States (Pienta et al., 2008) concluded that newer, more bio-
logically relevant models were still required. Although pure
transgenic models have permitted the dissection of basic
biological processes underlying prostate cancer, such as the
importance of PTEN (phosphatase and tensin homolog)
haploinsufficiency (i.e., Di Cristofano et al., 1998), as murine
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cells are not particularly susceptible to vectors targeting
human cancers, and oncolytic adenoviruses do not grow in
murine cells, testing systems are usually restricted to human
xenografts.
Just as with cell culture lines, until the early 1990s, the
limited number of xenograft models for prostate cancer re-
presented predominantly late-stage disease, whereas models
of untreated tumors were underrepresented (i.e., radical
prostatectomy samples). The more recent establishment of
‘‘early-stage’’ xenograft models and cell lines has largely
overcome this limitation (Tables 1 and 2). The latter xeno-
graft models (van Weerden et al., 1996, 2009; Marques, 2006)
have become even more relevant as prostate cancer is being
diagnosed at an earlier stage. Until more recently, for the
testing of gene therapy vectors, the field still remained
heavily dependent on the LNCaP, PC3, and DU145 cell lines.
PC3/DU145 Xenografts
PC3 cells form reproducible tumors at most murine sites
of inoculation, as subcutaneous, subrenal capsule, and in-
traprostatic orthotopic grafts (see review by Hoffman, 2007).
The tumors are capable of killing the host with an inocula-
tion of about half a million cells within 28 days. This ex-
tremely rapid growth from an undifferentiated epithelial cell
mass has been used extensively as the target for many
prostate-specific therapies. DU145 cells are similarly tumor-
igenic in immunocompromised animals, although they have
been used less frequently (Nemeth et al., 1999).
New variants expressing indicator genes such as luciferase
and green fluorescent protein (GFP) have been developed,
and more metastatic variants of PC3 have been selected by
prolonged passage in nude mice. It could be argued that the
lack of structure in the tumors and the rapid growth are not
comparable with human prostate cancers, which are much
slower growing and display elements of organization and
structure even in their least differentiated forms, as described
originally by Gleason (1966). One complication with PC3 is
that bone tumors, which can be obtained by direct inocula-
tion into bone (Nemeth et al., 1999), are oncolytic rather than
osteoblastic, as is commonly found in advanced human
cancers (see review by Dotan, 2008).
LNCaP Xenografts
In contrast, the LNCaP cell line expresses androgen re-
ceptor (albeit a mutant androgen receptor), which typifies
luminal differentiation in well-differentiated common pros-
tate cancers. However, xenografting with LNCaP can be
technically difficult, in particular to subcutaneous sites. It is
also capable of throwing off many substrains and the C4-2
series originally described by Thalmann and colleagues
(1994) clearly has the capacity not only to engraft but also to
induce metastasis.
The success of LNCaP xenografts can, however, be sub-
stantially improved by coinoculation with prostate stromal
cells (Tuxhorn et al., 2002). This again mimicks much more
closely the situation in humans.
Other Prostate Epithelial Cell Line Xenografts
The BPH1 cell line, which derived originally from benign
prostatic hyperplasia epithelium by introduction of SV40T
antigen (Hayward et al., 1995), can be induced to form ag-
gressive tumors by grafting subrenally in the presence of
carcinoma-associated fibroblasts (CAFs) from prostate
(Hayward et al., 2001). This again emphasizes the importance
of the epithelial–stromal interaction in the development of
prostate cancers both in vitro and in vivo. The mechanism for
this oncogenic transformation of a previously benign cell
type simply by the presence of fibroblasts is thought to occur
through a complex series of interactions, at least some of
which involve transforming growth factor (TGF)-b signaling
(Ao et al., 2007). To authentically model lower grades of
prostate cancer in the mouse environment will probably re-
quire such multicellular grafts.
PC346C Xenografts
The more recently established PC346C cells reliably form
undifferentiated epithelial tumors after subcutaneous or in-
traprostatic orthotopic inoculation of 1 million cells within 20
days. Importantly, PC346C is androgen sensitive, expresses a
wild-type androgen receptor, and secretes large amounts of
prostate-specific antigen, which typifies well-differentiated
common prostate cancers. Prolonged culture of PC346C cells
in the absence of androgen and=or in the presence of the
antiandrogen hydroxyflutamide, as well as in vivo passage in
castrate recipient mice, has resulted in several castration-
resistant variants (Marques et al., 2005, 2006). Furthermore,
orthotopic injection of PC346C has provided variant sublines
derived from metastatic lesions (lymph node and lung) that
are equally tumorigenic (W.M. van Weerden, unpublished
data). At present, PC346C variants expressing indicator
genes such as luciferase and GFP or RFP fluorescence are
being developed, which will permit real-time monitoring of
tumor cell fate.
Within the GIANT program we chose to exploit the latter
xenografts (for a review see Van Weerden et al., 2009), which
have been selected to span a range of pathologies, from an-
drogen dependency through to androgen independency and
a number of different morphologies and histological grades
(see Table 2).
Tumors of early prostate cancer, as represented by the
androgen-responsive PC82, PC295, and PC310 xenografts,
are well-differentiated tumors with a cribriform growth
pattern that continue to express the prostate antigens and
more critically a wild-type androgen receptor (Fig. 2E). In
contrast, xenografts that represent later stage disease, such as
PC133, PC135, and PC339, are relatively undifferentiated.
Xenografts are propagated by tumor fragment transplan-
tation without additional human stromal cells. Instead, tu-
mors are supported by infiltrating murine prostate stroma,
which provides the required vascularization and putative
stroma-derived factors that may be required for xenograft
growth. These xenografts have growth rates that are variable
between the various models, with relatively slow growth
rates for the androgen-responsive tumors (tumors reaching a
volume of 500mm3 by 60–70 days after transplantation) and
faster growth rates for the less differentiated xenografts
(tumors reaching a volume of 500mm3 by 30–40 days after
transplantation). Also, as the tumors continue to secrete
prostate-specific antigen (PSA), the principal biomarker for
clinical studies of prostate cancer (van Weerden and
Schro¨der, 2008), tumor growth can be readily monitored.
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The limitation of the xenograft panel largely lies in the fact
that these tumors, except for PC346, can be propagated only
subcutaneously, as we have been unable so far to establish
permanent cell lines from these xenograft models. Because
subcutaneously grown tumors generally do not metastasize,
these tumors cannot be used to study metastasis from the
primary site. However, PC346C cells that are inoculated into
the prostate have been shown to spread to other organs
(metastases in the lymph nodes and lung). For preclinical
testing, the GIANT program has employed the PC346C
tumor, which has the great advantage of being able to be
grown in vitro and as a serially transplanted xenograft. The
ability of PC346C cells to sustain virus growth has been
previously demonstrated (Kraaij et al., 2005), and several
prostate-specific oncolytic adenoviral vectors, such as Ad[I=
PPT-E1A] (Cheng et al., 2006) and Ad-ZH=3 (Magnusson
et al., 2007), have now been preclinically validated using the
orthotopic PC346C xenograft model. (Fig. 2F; and R. Kraaij,
unpublished).
Future Considerations/Outlook
The potential of gene therapy to provide an alternative
treatment for prostate cancer has been discussed since the
early 1990s (Sanda et al., 1994). The early promise has not yet
been fulfilled, although we now know a great deal more
about how to kill the correct cells, and perhaps more im-
portantly how to target potent therapies to the correct cell
types. Sadly, the testing strategies have failed to maintain the
rapid pace of advance in agent development, which could
account in part for the failure to convert our basic knowledge
into clinical trials.
The translation from cell lines in culture, and of rapidly
growing xenografts of the same cell lines, to a heterogeneous
and relatively slowly growing tumor in an immunocompetent
patient is rarely considered in vector development strategies.
We have attempted to highlight the difficulties in achieving
total tumor infection as a result of restrictions in vector spread
by using adenoviral vectors as a common example. The re-
striction of spread from a needle injection in tissues remains
limited to at best a few millimeters, requiring precise location
of the tumor to be infected (Patel et al., 2009). By treating the
vector inoculum as a medicine, requiring formulation just like
a small molecule, we can perhaps reduce the in vivo restric-
tions. For example, blockade of the innate immune response,
and incorporation of tissue disruptors such as relaxins (or
equivalent small molecules) to open tight junctions and reveal
receptors, would aid such spread.
However, the most important consideration must remain
patient selection: the stage of prostate cancer to be targeted,
and the critical realization that responses in each individual
human will vary and also differ from those in mouse models.
Increasingly, these responses can now be modeled in the
laboratory, restricting unnecessary time and expenditure on
premature clinical trials.
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